MYASTHENIA GRAVIS AND MULTIPLE SCLEROSIS

An uncommon presentation

Paulo J. Lorenzoni, Rosana H. Scola, Cláudia S. Kamoi Kay, Lineu C. Werneck

Myasthenia gravis (MG) is an autoimmune disease that compromises neuromuscular transmission and is mediated by autoantibodies against acetylcholine receptors on the postsynaptic membrane¹. In its usual form it leads to symptoms of decreased muscle strength and fatigue¹. Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system that shows a wide range of clinical features and a variable natural history². There is some evidence that patients with MG or MS have a higher risk of developing autoantibodies and other neuroimmune disorders than normal controls^{3,4}.

An autoimmune pathogenesis is implicated in both MG and MS, but the coexistence of the two disorders has rarely been documented, and for this reason we report this case⁴.

CASE

A 28-year-old woman presented with diplopia, dysphagia and mild limitation of ocular movements, with progressive palpebral ptosis and weakness, which changed in intensity from day to day and during the day according to the patient's physical activity.

Physical examination did not reveal any abnormalities. On neurological examination she was found to have asymmetrical palpebral ptosis (left>right); symmetrical muscle weakness (grade 4 on the MRC scale) in the proximal upper and lower limbs; and deep tendon reflexes. Gait and all sensory examinations were normal.

The investigation yielded the following results: (1) positive anti-acetylcholine receptor antibody test (14.91 nmol/L; normal < 0.20 nmol/L); (2) normal needle electromyography and nerve conduction studies; (3) repetitive stimulation of the facial, spinal accessory and ulnar nerves at 3 Hz with a decrement of more than 10% in compound muscle action potential amplitude (Fig 1); and (4) improvement of symptoms after treatment with pyridostigmine (180 mg daily). Chest computed tomography scan was normal.

A diagnosis of MG was made, and the patient showed an improvement in symptoms after she started to receive prednisone and pyridostigmine. Prednisone was discontinued after one year




Fig 1. Repetitive stimulation at 3 Hz showing a 26.3% amplitude decrement in compound muscle action potential in the facial nerve recorded from the orbicularis oculi muscle (A), a 24.4% decrement in the spinal accessory nerve recorded from the trapezius muscle (B), and a 12.3% decrement in the ulnar nerve recorded from the abductor digiti quinti muscle (C).

and was followed by oral administration of azathioprine (100 mg/day), with an improvement in palpebral ptosis and muscle strength (grade 5 on the MRC scale).

When she was 32 years old and still on azathioprine treatment, the patient developed a sudden weakness in her left lower limb and was treated with prednisone (60 mg/day). After this new neurological manifestation suggestive of MS, the patient was submitted to brain magnetic resonance imaging (MRI), which revealed multiple areas of high signal on FLAIR and T2-weighted images in the periventricular and subcortical white matter of the brain hemispheres (Fig 2A).

MIASTENIA GRAVIS E ESCLEROSE MÚLTIPLA: UMA APRESENTAÇÃO INCOMUM

Neurology Division, Internal Medicine Department, Hospital de Clínicas da Universidade Federal do Paraná (UFPR), Curitiba PR, Brazil.

Received 6 September 2007, received in final form 2 January 2008. Accepted 16 February 2008.

Dra. Rosana Herminia Scola — Serviço de Doenças Neuromusculares / Hospital de Clínicas da UFPR - Rua General Carneiro 181 / 3º andar - 80060-900 Curitiba PR - Brasil. E-mail: scola@hc.ufpr.br




Fig 2. (A) First relapse (2003): multiple areas of high signal on axial FLAIR and T2-weighted images in the periventricular and subcortical white matter of the brain hemispheres. (B) Second relapse (2006): high signal on axial and sagittal FLAIR images in some periventricular and subcortical areas of white matter of the brain hemispheres.

Three years later, she presented with a sudden episode of deafness, paresthesia and weakness in her left lower limb. Neurological examination showed nystagmus; left facial paresis; bilateral hearing loss; muscle strength grade 4 (MRC scale) in the left lower limb; bilateral increased deep tendon reflexes in the lower limbs; left Babinski sign; gait ataxia; and impaired pain, temperature, pinprick and light touch sensory examinations in the left lower limb. Vibration sensibility and joint position sense also revealed impairment in the left lower limb.

MRI showed new areas of high signal on FLAIR and low signal on TI-weighted images in the periventricular and subcortical white matter of the brain hemispheres as well as in the cerebellum (Fig 2B).

Hematological tests, biochemistry screening and thyroid function were normal, and serological tests for HIV and HTLV were negative. Anti-nuclear antibody test (1:640 with diffuse pattern; normal <1:40) and anti-SSB/La (13.8 U/mL; normal <10 U/mL) were positive, but the other serum antibody tests (anti-RNP, Sm and SSA/Ro) were negative. Cerebrospinal fluid analysis was normal with a normal electrophoretic protein pattern.

The patient was diagnosed as having had another MS relapse (her disability EDSS score was 5.5) combined with MG. Intravenous methylprednisolone pulse therapy was started, with substantial improvement in muscle strength in the left lower limb. Currently the patient is receiving azathioprine, and her disability EDSS score is 4.5 after five years of follow-up.

All studies were carried out following informed consent.

DISCUSSION

MG is a rare disease with a prevalence ranging between 0.5 and 15.0 cases per 100000 inhabitants and an incidence of 0.4 to 1.1 cases per 100000 inhabitants^{1,5}. In Brazil there are probably 15500 persons affected by MG⁶. In a number

of studies of MS, a variation in prevalence and clinical pattern with geographical location was observed, probably related to ethnic and environmental factors^{2,7}. With 15.0 cases of MS per 100000 inhabitants, Brazil is considered to have a low prevalence, particularly compared with other countries at similar latitudes⁷. The probability of the same patient developing both of these disorders is extremely low, although it should be remembered that these patients are more likely to develop other autoimmune diseases than patients without immune-mediated disorders⁸.

However, the combination of these two diseases occurs at rates higher than those expected by random association and appears to be more common than estimated. An epidemiological survey in Finland found that two persons in a population of 1.5 million had combined MG and MS. As the expected combined prevalence was 3.6 cases per 100 million people, the prevalence identified in the study was 37 times greater than that expected³. A similar study in Canada found a significantly higher prevalence than that predicted by estimates of the prevalence of this combination of disorders⁴.

This nonrandom association of MG and MS in patients could support the hypothesis of an immunological mechanism of pathogenesis common to both disorders^{4,9}. The Finnish study referred to above speculated that a similar immunogenetic background predisposes to susceptibility to these two disorders but that unknown genetic factors and different triggering factors result in two different clinical diseases^{3,9}. The same might be said of the increased occurrence of other autoimmune disorders such as systemic lupus erythematosus in patients with MG⁸.

The clinical onset of MS can be observed before or after the development of MG, and the time to onset of this association can vary from 1 to 28 years^{3,9}. The patients were young and predominantly female and appear to fit the typical demographic characteristics for both MS and the younger peak of the bimodal age distribution in MG, as in our case⁴. According to case reports, the clinical course of both MG and MS is mild in most patients with this combination of neuroimmunological disorders, but the onset of MG could cause an exacerbation of MS, whereas MG can be relatively unaffected by fluctuations in the clinical course of MS^{3,4}. Neurologists must bear in mind that patients with MG who present with atypical clinical characteristics or evolution can have other associated autoimmune disorders, such as MS, and, as in our case, these patients should be submitted to others tests, such as brain imaging, for differential diagnosis.

Antinuclear antibodies (ANAs) occur more frequently in patients with MS or MG than in the general population, and their presence often causes uncertainty in the diagnosis of these two diseases ¹⁰⁻¹². ANAs usually occur in 20 to 30% of MS patients and can be observed in almost 40% of MG patients ¹¹⁻¹³. The high frequency of ANAs in MS and MG probably reflects ongoing systemic immune dysregulation ¹¹⁻¹³.

The most recent descriptions of this association refer to the onset of MG in MS patients during immunomodulatory drug treatment 4,14,15 . The development of MG during interferon- β or glatiramer acetate treatment has two possible explanations: first, it may be a coincidental autoimmune disorder, as sporadically described in the literature; or, second, it may be triggered by the treatment with these drugs as a result of deviation of the immune response towards enhanced Th2 cell reactions 14,15 .

The patients reported in the international literature in whom MG occurred before MS were not on immunosuppressive therapy at the onset of MS⁴. Azathioprine is of-

ten considered for the treatment of patients with MG and can be used for the management of MS. The development of central nervous system demyelinating diseases, such as acute myelitis or disseminated encephalomyelitis, after the start of MG treatment with azathioprine has been reported previously, supporting the possibility that immune modulating treatments may play a role in the immunological mechanism of pathogenesis of this combination¹⁰. However, the development of MS in a patient with MG during treatment with azathioprine has not been reported to date.

REFERENCES

- Cunha FMB, Scola RH, Werneck LC. Myasthenia gravis: clinical evaluation of 153 patients. Arq Neuropsiquiatr 1999;57:457-464.
- Arruda WO, Scola RH, Teive HAG, Werneck LC. Multiple sclerosis: report on 200 cases from Curitiba, Southern Brazil and comparison with others Brazilian series. Arq Neuropsiquiatr 2001;59:165-170.
- Somer H, Muller K, Kinnunen E. Myasthenia gravis associated with multiple sclerosis, epidemiological survey and immunological findings. J Neurol Sci 1989;89:37-48.
- 4. Isbister CM, Mackenzie PJ, Anderson D, Wade NK, Oger J. Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia. Mult Scler 2003;9:550-553.
- Sanchez JL, Uribe CS, Franco A, Jimenez ME, Arcos-Burgos M, Palacio LG. Prevalence of myasthenia gravis in Antioquia, Colômbia. Rev Neurol 2002;34:1010-1012.
- 6. Assis JL. Miastenia gravis. São Paulo: Savier, 1990: 10.
- Callegaro D, Goldbaum M, Morais L, et al. The prevalence of multiple sclerosis in the city of São Paulo, Brazil, 1997. Acta Neurol Scand 2001;104:208-213.
- Carvalho MF, Abrahão TCM, Assaf M. Systemic lupus erythematosus and myasthenia gravis: case report. Arq Neuropsiquiatr 1998;56:137-140.
- Keesey JC. Does myasthenia gravis affect the brain? J Neurol Sci 1999:170:77-89
- Gotkine M, Fellig Y, Abramsky O. Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology 2006;67:881-883.
- Collard RC, Koehler RPM, Mattson DH. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 1997;49:857-861.
- Sthoeger Z, Neiman A, Elbirt D, et al. High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic study. Am J Med Sci 2006;331:4-9.
- Barned S, Goodman AD, Mattson DH. Frequency of anti-nuclear antibodies in multiple sclerosis. Neurology 1995;45:384-385.
- Dionisiotis J, Zoukos Y, Thomaides T. Development of myasthenia gravis in two patients with multiple sclerosis following interferon b treatment. J Neurol Neurosurg Psychiatry 2004;75:1076-1079.
- Frese A, Bethke F, Lüdemann P, Stögbauer F. Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate. J Neurol 2000;247:713.